

Meitheal Pharmaceuticals Clofarabine Injection

Vermont New Drug Report

Product Name & Description	Clofarabine Injection 20mg 20 mL (10mg/mL) SDV
NDC	71288-0128-20
WAC Price	\$800.00
Effective Date	3/24/2021
Description of Marketing/Pricing Plan	<p>Meitheal markets generic clofarabine as a therapeutic equivalent to the innovator (brand) drug. As such, Meitheal relies on the safety and efficacy findings of the FDA with respect to the innovator drug. Meitheal markets to group purchasing organizations (GPOs), Integrated Delivery Networks (IDNs), and hospital/alternate site (own use) customers based solely on price and availability and therefore does not engage in direct-to-consumer, direct-to-physician, or prescriber marketing. Meitheal does not market based on any aspects of the drug itself, nor does Meitheal aim to treat a certain number of patients. Rather, Meitheal evaluates the size of the total market for a particular drug and strives to achieve a certain market share for that product.</p>
Estimated Patient Population	<p>Because its clofarabine product is a generic product and there are a number of alternative options available, Meitheal Pharmaceuticals does not track the number of patients that are prescribed clofarabine. As such, given clofarabine's primary use for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients under the age of 21, Meitheal's best estimate regarding a patient population can be derived from the Centers for Disease Control and Prevention's ("CDC") tracking of ALL diagnoses within the United States. According to the CDC's most recent data (in 2017), the number of new cases of ALL in pediatric patients is 3,000 or more. (https://www.cdc.gov/mmwr/volumes/66/wr/mm6636a3.htm).</p>
Breakthrough Therapy/Priority Review	N/A
Date and price of acquisition	N/A